[{"id":"a8dbbb89-8bb1-4f12-ad96-eb67e83dce09","acronym":"","url":"https://clinicaltrials.gov/study/NCT00265798","created_at":"2021-01-18T00:54:12.869Z","updated_at":"2025-02-25T13:47:55.628Z","phase":"Phase 2","brief_title":"Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","source_id_and_acronym":"NCT00265798","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • imatinib • sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 09/14/2005","start_date":" 09/14/2005","primary_txt":" Primary completion: 02/11/2010","primary_completion_date":" 02/11/2010","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2025-02-20"},{"id":"d77f7e27-d759-4800-bb9d-f2404753c9ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT06222593","created_at":"2024-01-24T15:19:20.942Z","updated_at":"2025-02-25T14:10:34.092Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC","source_id_and_acronym":"NCT06222593","lead_sponsor":"State University of New York at Buffalo","biomarkers":" AR • KLK2","pipe":" | ","alterations":" AR expression • KLK2 expression","tags":["AR • KLK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • KLK2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • bicalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-17"},{"id":"c2c0bdf4-79cd-4e7d-b1f6-9bf7bf2f7d00","acronym":"SAVOIR","url":"https://clinicaltrials.gov/study/NCT03091192","created_at":"2021-01-17T17:49:25.734Z","updated_at":"2025-02-25T15:10:33.304Z","phase":"Phase 3","brief_title":"Savolitinib vs. Sunitinib in MET-driven PRCC.","source_id_and_acronym":"NCT03091192 - SAVOIR","lead_sponsor":"AstraZeneca","biomarkers":" VHL","pipe":" | ","alterations":" VHL mutation","tags":["VHL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/25/2017","start_date":" 07/25/2017","primary_txt":" Primary completion: 08/18/2019","primary_completion_date":" 08/18/2019","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-13"},{"id":"7ae66fef-a243-4d8f-b364-a73eb3507cdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633122","created_at":"2021-01-19T20:36:54.322Z","updated_at":"2025-02-25T15:34:48.949Z","phase":"Phase 2","brief_title":"A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib","source_id_and_acronym":"NCT04633122","lead_sponsor":"Zai Lab (Shanghai) Co., Ltd.","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Qinlock (ripretinib)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 11/25/2020","start_date":" 11/25/2020","primary_txt":" Primary completion: 07/20/2022","primary_completion_date":" 07/20/2022","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2025-02-10"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"4baf504a-3428-46d7-aa11-1c6d5b48f340","acronym":"ACTION-1","url":"https://clinicaltrials.gov/study/NCT05477576","created_at":"2022-07-28T14:55:31.876Z","updated_at":"2025-02-25T17:37:59.568Z","phase":"Phase 3","brief_title":"Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","source_id_and_acronym":"NCT05477576 - ACTION-1","lead_sponsor":"RayzeBio, Inc.","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • lanreotide prolonged-release subcutaneous • octreotide acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 288","initiation":"Initiation: 03/24/2022","start_date":" 03/24/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-01-29"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"b25768d2-e63d-4ef1-89e9-0d4fc5455a84","acronym":"StrateGIST 1","url":"https://clinicaltrials.gov/study/NCT05489237","created_at":"2022-08-05T13:57:06.723Z","updated_at":"2025-02-25T13:13:05.882Z","phase":"Phase 1","brief_title":"First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT05489237 - StrateGIST 1","lead_sponsor":"IDRx, Inc.","biomarkers":" PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation • PDGFRA exon 18 mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation • PDGFRA exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • velzatinib (GSK6042981)"],"overall_status":"Recruiting","enrollment":" Enrollment 269","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 04/24/2026","primary_completion_date":" 04/24/2026","study_txt":" Completion: 09/13/2026","study_completion_date":" 09/13/2026","last_update_posted":"2025-01-17"},{"id":"1cc3eb18-79f5-432b-996d-68c0fa40cdd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06772233","created_at":"2025-02-26T06:55:02.549Z","updated_at":"2025-02-26T06:55:02.549Z","phase":"Phase 2","brief_title":"A Study of Regorafenib Combined with Envafolimab for Metastatic Gastrointestinal Stromal Tumors with Kit Gene Exon 17 Mutation That Failed Standard Treatment","source_id_and_acronym":"NCT06772233","lead_sponsor":"Peking University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Stivarga (regorafenib) • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-01-13"},{"id":"613dfa54-e318-471f-a8ed-a12b2572968b","acronym":"CAPTUR","url":"https://clinicaltrials.gov/study/NCT03297606","created_at":"2021-01-18T16:17:30.914Z","updated_at":"2025-02-25T13:52:23.697Z","phase":"Phase 2","brief_title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","source_id_and_acronym":"NCT03297606 - CAPTUR","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • bosutinib • Tukysa (tucatinib) • temsirolimus • axitinib • Erivedge (vismodegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-11-12"},{"id":"e0869b70-da93-469e-910d-a5ac1a29c3a4","acronym":"LENVAGIST","url":"https://clinicaltrials.gov/study/NCT04193553","created_at":"2025-09-06T15:32:52.730Z","updated_at":"2025-09-06T15:32:52.730Z","phase":"Phase 2","brief_title":"Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure","source_id_and_acronym":"NCT04193553 - LENVAGIST","lead_sponsor":"Centre Leon Berard","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 01/17/2020","start_date":" 01/17/2020","primary_txt":" Primary completion: 01/30/2024","primary_completion_date":" 01/30/2024","study_txt":" Completion: 04/26/2024","study_completion_date":" 04/26/2024","last_update_posted":"2024-06-18"},{"id":"eb48e074-c9c1-4740-b335-db17f9ac4451","acronym":"PAPMET","url":"https://clinicaltrials.gov/study/NCT02761057","created_at":"2024-02-04T01:56:06.891Z","updated_at":"2024-07-02T16:34:26.084Z","phase":"Phase 2","brief_title":"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","source_id_and_acronym":"NCT02761057 - PAPMET","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" MET mutation • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET mutation • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • sunitinib • Cabometyx (cabozantinib tablet) • Orpathys (savolitinib) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 07/25/2016","start_date":" 07/25/2016","primary_txt":" Primary completion: 10/02/2023","primary_completion_date":" 10/02/2023","study_txt":" Completion: 12/12/2024","study_completion_date":" 12/12/2024","last_update_posted":"2024-06-14"},{"id":"facca190-15a5-41db-a54e-ca426babdb55","acronym":"CABOSUN II","url":"https://clinicaltrials.gov/study/NCT03541902","created_at":"2021-01-18T17:25:42.722Z","updated_at":"2024-07-02T16:34:36.884Z","phase":"Phase 2","brief_title":"Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma","source_id_and_acronym":"NCT03541902 - CABOSUN II","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" mTOR","pipe":"","alterations":" ","tags":["mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Cabometyx (cabozantinib tablet)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/15/2018","start_date":" 05/15/2018","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-06-10"},{"id":"90e2c2df-d5c6-4f93-8b0d-0ff266e30b82","acronym":"","url":"https://clinicaltrials.gov/study/NCT01306045","created_at":"2021-01-18T05:18:49.422Z","updated_at":"2024-07-02T16:35:10.788Z","phase":"Phase 2","brief_title":"Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies","source_id_and_acronym":"NCT01306045","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • sunitinib • lapatinib • Koselugo (selumetinib) • MK-2206"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 647","initiation":"Initiation: 02/08/2011","start_date":" 02/08/2011","primary_txt":" Primary completion: 02/12/2014","primary_completion_date":" 02/12/2014","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-09"},{"id":"cb8d2781-175e-47d3-a3e8-c2f88771d5b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00381641","created_at":"2023-11-22T18:15:18.641Z","updated_at":"2024-07-02T16:35:11.050Z","phase":"Phase 2","brief_title":"Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery","source_id_and_acronym":"NCT00381641","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RET","pipe":"","alterations":" ","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/08/2006","start_date":" 08/08/2006","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2024-04-08"},{"id":"47aa2393-a124-415e-825e-d17be7197efa","acronym":"NCI-2018-00192","url":"https://clinicaltrials.gov/study/NCT03463460","created_at":"2021-01-18T17:04:23.138Z","updated_at":"2024-07-02T16:35:14.545Z","phase":"Phase 2","brief_title":"Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer","source_id_and_acronym":"NCT03463460 - NCI-2018-00192","lead_sponsor":"Dwight Owen","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • sunitinib"],"overall_status":"Suspended","enrollment":" Enrollment 30","initiation":"Initiation: 06/19/2018","start_date":" 06/19/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-15"},{"id":"afe5eda5-b0b2-4528-9023-e2c1d7118027","acronym":"","url":"https://clinicaltrials.gov/study/NCT05905887","created_at":"2023-06-15T17:08:41.962Z","updated_at":"2024-07-02T16:35:17.151Z","phase":"Phase 2","brief_title":"Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor","source_id_and_acronym":"NCT05905887","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • imatinib • sunitinib • AiTan (rivoceranib) • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-02-28"},{"id":"afe413d7-7e85-457e-9af3-9c556a34d9ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT01396408","created_at":"2021-01-18T05:44:09.814Z","updated_at":"2024-07-02T16:35:17.762Z","phase":"Phase 2","brief_title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT01396408","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PTEN • STK11 • NF1","pipe":" | ","alterations":" EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification","tags":["PTEN • STK11 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • temsirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 02/09/2012","start_date":" 02/09/2012","primary_txt":" Primary completion: 07/06/2015","primary_completion_date":" 07/06/2015","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-26"},{"id":"4c2f1c18-6e61-4a09-9dd2-0ccca96142b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03944304","created_at":"2021-01-18T19:25:15.034Z","updated_at":"2024-07-02T16:35:24.855Z","phase":"Phase 2","brief_title":"Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.","source_id_and_acronym":"NCT03944304","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • imatinib • sunitinib • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/27/2019","start_date":" 05/27/2019","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-01-01"},{"id":"4940e693-9465-46a4-adde-f09648b1d496","acronym":"JAVELIN Renal 101","url":"https://clinicaltrials.gov/study/NCT02684006","created_at":"2021-01-17T17:21:28.108Z","updated_at":"2024-07-02T16:35:25.303Z","phase":"Phase 3","brief_title":"A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)","source_id_and_acronym":"NCT02684006 - JAVELIN Renal 101","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Bavencio (avelumab) • axitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 888","initiation":"Initiation: 03/23/2016","start_date":" 03/23/2016","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 05/21/2024","study_completion_date":" 05/21/2024","last_update_posted":"2023-12-22"},{"id":"6930bd13-a689-4284-b6bf-affbebb0e167","acronym":"","url":"https://clinicaltrials.gov/study/NCT05366816","created_at":"2022-05-09T11:56:34.398Z","updated_at":"2024-07-02T16:35:32.170Z","phase":"Phase 2","brief_title":"ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST","source_id_and_acronym":"NCT05366816","lead_sponsor":"University of Miami","biomarkers":" KIT","pipe":" | ","alterations":" KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT exon 13 mutation • KIT exon 17 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/17/2023","start_date":" 10/17/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-10-23"},{"id":"9029b63b-49b7-4f5b-bf2d-d1dd5f6be242","acronym":"","url":"https://clinicaltrials.gov/study/NCT04006769","created_at":"2021-01-18T19:41:21.824Z","updated_at":"2024-07-02T16:35:32.887Z","phase":"Phase 1","brief_title":"Entacapone Combination With Imatinib for Treatment of GIST","source_id_and_acronym":"NCT04006769","lead_sponsor":"Xiangya Hospital of Central South University","biomarkers":" KIT • FTO","pipe":" | ","alterations":" KIT mutation • KIT expression • FTO expression","tags":["KIT • FTO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT expression • FTO expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 10/30/2020","start_date":" 10/30/2020","primary_txt":" Primary completion: 08/31/2022","primary_completion_date":" 08/31/2022","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2023-10-18"},{"id":"576ff15e-7a07-4123-9e2a-6f4a1fed07d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00813423","created_at":"2021-01-18T03:05:24.899Z","updated_at":"2024-07-02T16:35:41.219Z","phase":"Phase 1","brief_title":"Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy","source_id_and_acronym":"NCT00813423","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD31 • ENG • PECAM1 • BECN1","pipe":"","alterations":" ","tags":["CD31 • ENG • PECAM1 • BECN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 02/19/2010","start_date":" 02/19/2010","primary_txt":" Primary completion: 07/18/2023","primary_completion_date":" 07/18/2023","study_txt":" Completion: 07/18/2023","study_completion_date":" 07/18/2023","last_update_posted":"2023-08-02"},{"id":"2b362821-228e-4647-ab9a-04854ffc8751","acronym":"","url":"https://clinicaltrials.gov/study/NCT05381753","created_at":"2022-05-19T12:57:08.164Z","updated_at":"2024-07-02T16:35:43.571Z","phase":"","brief_title":"Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World","source_id_and_acronym":"NCT05381753","lead_sponsor":"CStone Pharmaceuticals","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 08/29/2022","start_date":" 08/29/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-07-10"}]